Contract Pharma Staff10.29.20
Avomeen has appointed Luke Miller, Ph.D. as its senior vice president of lab operations. In this position, Miller will further strengthen and expand Avomeen’s laboratory operations to support the company’s continued growth.
“Luke brings a wealth of knowledge and expertise in operations strategy, team development, and lab design and optimization,” said Mark Harvill, Avomeen chief executive officer. “His leadership and expertise will be invaluable as we continue to grow and expand our Life Sciences and Nicotine service offerings and teams, ensuring our clients receive the exceptional service they have come to expect from Avomeen.”
Miller comes to Avomeen with more than 25 years of experience in lab operations and leadership in the biopharmaceutical and CDMO industries. Most recently, he served as the vice president of lab operations at Metabolon. There, he managed facilities across a global network; co-developed and launched an assay for inborn error of metabolism screening; co-developed and launched a platform for analysis of complex lipids in mammalian samples; and extracted, identified and patented a previously unidentified, novel biomarker for insulin resistance. Prior to this, he held a position as a director of analytical chemistry in Drug Discovery at GlaxoSmithKline.
Throughout his career, Miller has developed extensive expertise in engineering and oversight of high-volume, high-throughput labs, including instruments, consumables, process optimization, lab order and compliance, leadership and engagement of staff, small and large molecule methods and analysis and the translation of those methods and techniques into more routine services.
Miller holds a doctorate degree in analytical chemistry from the University of Reading, United Kingdom and a bachelor’s double honors degree in chemistry and management from City University of London.
“Luke brings a wealth of knowledge and expertise in operations strategy, team development, and lab design and optimization,” said Mark Harvill, Avomeen chief executive officer. “His leadership and expertise will be invaluable as we continue to grow and expand our Life Sciences and Nicotine service offerings and teams, ensuring our clients receive the exceptional service they have come to expect from Avomeen.”
Miller comes to Avomeen with more than 25 years of experience in lab operations and leadership in the biopharmaceutical and CDMO industries. Most recently, he served as the vice president of lab operations at Metabolon. There, he managed facilities across a global network; co-developed and launched an assay for inborn error of metabolism screening; co-developed and launched a platform for analysis of complex lipids in mammalian samples; and extracted, identified and patented a previously unidentified, novel biomarker for insulin resistance. Prior to this, he held a position as a director of analytical chemistry in Drug Discovery at GlaxoSmithKline.
Throughout his career, Miller has developed extensive expertise in engineering and oversight of high-volume, high-throughput labs, including instruments, consumables, process optimization, lab order and compliance, leadership and engagement of staff, small and large molecule methods and analysis and the translation of those methods and techniques into more routine services.
Miller holds a doctorate degree in analytical chemistry from the University of Reading, United Kingdom and a bachelor’s double honors degree in chemistry and management from City University of London.
